Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective

Abstract

BACKGROUND: The U.S. health care system's transition to a value-based reimbursement model holds important implications for medical innovation, care delivery, and value-based assessments of therapeutic interventions. This transition has been especially noteworthy in oncology, with substantial ongoing changes to payer reimbursement and the provider landscape, as well as the introduction of value frameworks to guide drug treatment decision making. The implications of these changes for provider assessments of drug value and evidence needs remain unclear.OBJECTIVES: To understand provider perspectives on drug value assessment and the utility of existing oncology value frameworks by identifying (a) key value-based trends in the evolving oncology landscape, (b) provider definitions of drug value, (c) the role of existing value frameworks in provider decision making, and (d) future provider evidence needs for making value-based treatment decisions. METHODS:We conducted a literature review to identify existing oncology value frameworks and definitions of drug treatment value in oncology. Using a structured discussion guide informed by this literature review, we conducted 12 telephone-based in-depth interviews in November and December 2017 with U.S. oncology providers involved in organizational drug treatment and formulary decision making within their practices. Responses to interview questions were analyzed and reported as averages and percentages across participants. RESULTS: Of 293 publications identified by keyword searches, 35 relevant articles were identified. Among these, the literature review identified no common definition for providers to assess drug value. Interview research participants described large ongoing changes in the oncology provider landscape, with economic pressures from payers as the foremost leading factor. Although 5 value frameworks were found in the literature, interviews found that in practice few providers consider these value frameworks to be key influences when evaluating treatment or formulary decisions. Furthermore, while 83% of participants' organizations employed some form of internal clinical pathways, only the minority (25%) with pathways integrated in their electronic medical record (EMR) systems saw these pathways as significantly affecting clinicians' drug treatment decision making. To aid the ongoing shift from volume-based to value-based care, we found that, rather than value frameworks, providers are looking for patient-level tools to make more appropriate drug decisions. CONCLUSIONS: Payer reimbursement pressures are leading to radical changes in the oncology provider landscape, and there is a need for improved guidance for providers in assessing drug value. In particular, this study identifies the need for a timely and multifaceted summary of information required to assess the value of alternative treatment options for a given patient. Manufacturers also need to make significant strides to help generate and improve the dissemination of evidence to support the value of their the...

Should We Consider Value Frameworks for Cancer Drugs as Oncology's Landscape Evolves?; from an Oncologist Perspective in Korea

“…Clinical efficacy was also ranked as the highest priority by US physicians, which is consistent with our study. 20 The interviewed US physicians acknowledged that cost/economic factors, system/organization, and social values played a limited role in influencing drug value assessment. However, at the same time, 83% of participants indicated that a patient's affordability was a key determinant of their perception of drug value.…”

Formulary management challenges and opportunities: 2020 and beyond ‐ an opinion paper of the drug information practice and research network of the American College of Clinical Pharmacy

“…The increasing cost of medications has resulted in a broadening of formulary categories (Table 5) as well as creative solutions to mitigate their financial impact using different pharmacoeconomic models (eg, cost‐minimization, cost utility) as relevant to the drug/disease state 36 . Five value frameworks exist within the oncology landscape, which share a focus on safety and survival but demonstrate variability in methodology and perspective in comparing value as well as framework‐specific advantages and disadvantages 37 . One health‐system implemented a value‐based approach toward formulary management of specialty medications that includes scored criteria for the assessment of efficacy, risk, cost, and societal benefit 38 .…”